scholarly journals The Association between Peri-Transplant RBC Transfusion and Graft Failure after Kidney Transplantation: A Nationwide Cohort Study

2021 ◽  
Vol 10 (16) ◽  
pp. 3750
Author(s):  
Kyungho Lee ◽  
Seohee Lee ◽  
Eun Jin Jang ◽  
Ga Hee Kim ◽  
Seokha Yoo ◽  
...  

Background: Patients undergoing kidney transplantation (KT) often receive red blood cell (RBC) transfusion during admission for KT which may increase the risk of allosensitization. The association between peri-transplant RBC transfusion and graft survival was evaluated using a nationwide cohort. Methods: This retrospective study analyzed 13,871 patients who underwent KT in Korea between 2007 and 2015. The outcomes were graft failure rate and overall patient survival depending on the amount of RBC transfusion. Results: The overall graft failure rate was 15.5%. Compared to the graft failure rate of 13.5% in the no transfusion group, the graft failure rate was 15.4% in the 1–2 units group (sHR 1.06 (95% CI 0.97–1.17), p = 0.216), 21.4% in the 3–5 units group (sHR 1.39 (1.21–1.61), p < 0.001), and 35.3% in the 6 or more units group (sHR 2.20 (1.70–2.85), p < 0.001). The overall survival rate was 97.5% in the no transfusion group, compared to 95.9% in the 1–2 units group (HR 1.50 (1.22–1.83), p < 0.001), 92.0% in the 3–5 units group (HR 2.43 (1.87–3.15), p < 0.001), and 67.5% in the 6 or more units group (HR 6.81 (5.03–9.22), p < 0.001). Conclusions: Peri-transplant RBC transfusion was independently associated with the increased risk of renal allograft failure and death in KT patients.

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Anissa Paschereit ◽  
Klemens Budde ◽  
Michael Dürr ◽  
Marcel Naik

Abstract Background and Aims Dialysis patients (pts) have an increased risk for hepatitis B (HB) infection and impaired response to HB vaccine compared to the general population. As shown in other studies, patient and graft survival in pts with chronic HB is worse. This study assesses the outcome of HBc-positive patients after kidney transplantation (KTx). Method In our retrospective analysis we included all patients &gt;18 years old, who underwent kidney transplantation from 01.01.1990 to 31.08.2019 in our center. Patients were grouped by their serostatus prior to kidney transplantation into “A: naïve” (HB negative), “B: HBc-positive” (non-active HB) and “C: HBsAg-positive” (chronic HB). Primary endpoints included patient and graft survival analyzed with Kaplan-Meier and log-rank test. Regression analysis was applied to determine independent risk factors for the occurrence of primary endpoints. Results In 2487 kidney transplant patients, serologic markers were retrievable. We identified n=2198 HB naïve, n=218 non-active HB and n=75 chronic HB pts. Overall 29.1% (A:27.7%, B:37.6%, C:45.3%) pts died and 20.3% (A:19.1%, B:27.5%, C:37.3%) pts suffered from graft failure. The 5-year pts survival (Fig. 1) was A: 87.0%, B: 82.8%, C: 82.2%. The 10-year pts survival was A: 71.7%, B: 61.1%, C: 64.5% and the 20-year pts survival was A: 43.1%, B: 26.1%, C: 40.9% (p=0.01). Kaplan-Meier-analysis showed a 5-year graft survival (Fig. 2) of 87.7% in the naïve, 86.1% in non-active HB and 84.3% in chronic HB group. The 10-year graft survival was A: 77.3%, B: 64.9%, C: 76% and the 20-year graft survival was A: 59.7%, B: 52.2%, C: 33.4% (p&lt;0.001). The overall 5-year pts and graft survival (Fig. 3) was A: 78.7%, B: 74.2%, C: 68.6%. The 10-year pts and graft survival was A: 59.8%, B: 46.4%, C: 51.8%. The 20-year overall rate was A: 30.8%, B: 26.4%, C: 14.9% (p&lt;0.001). Regression analysis (Table 1) showed that anti-HBs positivity (≥100 IE/l) was a protective factor for graft failure and death (p&lt;0.001). Conclusion HB leads to earlier graft loss and inferior patient survival. Beside the already known negative effect of chronic HB infection, also in patients with non-active HB infection overall survival was significant worse to HB naïve patients. Thus, non-active HB status is an important risk factor for overall transplant outcome. Next, influence of antiviral and immunosuppressive regimens and incidence of HB-reactivation are to be analyzed.


The Lancet ◽  
1990 ◽  
Vol 335 (8699) ◽  
pp. 1184-1185 ◽  
Author(s):  
A.W Harmer ◽  
S.P.A Rigden ◽  
C.G Koffman ◽  
K.I Welsh

2004 ◽  
Vol 4 (9) ◽  
pp. 1466-1474 ◽  
Author(s):  
Mario Rotondi ◽  
Alberto Rosati ◽  
Andrea Buonamano ◽  
Laura Lasagni ◽  
Elena Lazzeri ◽  
...  

2016 ◽  
Vol 32 (4) ◽  
pp. 679-684 ◽  
Author(s):  
Stephanie Dufek ◽  
Azaz Khalil ◽  
Nizam Mamode ◽  
Neil J. Sebire ◽  
Stephen D. Marks

2013 ◽  
Vol 6 (1) ◽  
Author(s):  
Moghaddameh Mirzaee ◽  
Jalal Azmandian ◽  
Hojjat Zeraati ◽  
Mahmood Mahmoodi ◽  
Kazem Mohammad ◽  
...  

1985 ◽  
Vol 39 (2) ◽  
pp. 147-150 ◽  
Author(s):  
P. S. PARFREY ◽  
T. A. HUTCHINSON ◽  
R. P. LOWRY ◽  
J. KNAACK ◽  
R. D. GUTTMANN

Sign in / Sign up

Export Citation Format

Share Document